← All Revelation Biosciences, INC filings

Revelation Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
REVB
Revelation Biosciences, INC
10-K: Revelation Biosciences Faces Going Concern Amidst Losses
Revelation Biosciences, a clinical-stage biotech, reported recurring losses and a going concern qualification, despite advancing its kidney disease drug candidates and recent capital raises.
NASDAQ
REVB
Revelation Biosciences, INC
10-K: Revelation Biosciences Reports 2024 Results, Initiates Phase 1b Study in CKD Patients
Revelation Biosciences, a clinical-stage life science company, announces its 2024 financial results and the start of a Phase 1b clinical study for Gemini-CKD in chronic kidney disease patients.
NASDAQ
REVB
Revelation Biosciences, INC
10-K/A: Revelation Biosciences Files Amended 10-K to Correct Certification Language
Revelation Biosciences has filed an amendment to its annual report to correct an omission in the certifications of its principal executive and financial officers.
NASDAQ
REVB
Revelation Biosciences, INC
10-K: Revelation Biosciences Files 10-K, Outlines Progress in Innate Immune System Therapeutics
Revelation Biosciences' 10-K filing details its focus on developing innate immune system therapeutics, including programs for surgical site infections, acute kidney injury, and chronic kidney disease.